NCT07249801 Closed-loop rTMS-EEG During Visuomotor Integration.
| NCT ID | NCT07249801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of South Carolina |
| Condition | Visuomotor Skills |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-11-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study aims at establishing personalized state-based rTMS for precision neurorehabilitation, we designed a within-subject cross-over study to test closed-loop repetitive transcranial magnetic stimulation and electroencephalography (rTMS-EEG) comparing the targeting of two key nodes in the frontoparietal network during bimanual visuomotor force tracking in persons with upper extremity sensorimotor impairment affecting eye-hand control.
Eligibility Criteria
Inclusion Criteria: * adult volunteers (age ≥18 years) * right-hand dominance (defined with the Edinburg Handedness Scale) * voluntary whole-hand grip force (Medical Research Council scale for muscle force ≥2) * capable of repeated grasp and release with 5% of maximum voluntary contraction (standardized with an in-house computer-based assessment involving whole-hand grip force tracking upon visual cues with a digital dynamometer). Exclusion Criteria: * presence of any MRI risk factors (such as an electrically, magnetically, mechanically activated metal or nonmetal implant including cardiac pacemaker, intracerebral vascular clips, any other electrically sensitive support system, or claustrophobia) * presence of any contraindications to repetitive transcranial magnetic stimulation, rTMS (e.g., history of seizures or epileptic activity, currently taking medications that lower seizure thresholds) * any neurological or psychiatric disorders affecting cognitive function (e.g., established dementia) affecting the ability to understand the purpose of the study and give informed consent or ability to complete cognitive testing * substance use disorder * visual impairment that precludes completion of scanner tasks * uncontrolled hypertension despite treatment * intake of tricyclic anti-depressants * musculoskeletal disorders affecting bimanual grasp- and release * pregnancy (or suspected/possible pregnancy or plan to become pregnant in the short term). If the participant is a woman of childbearing potential, a urine pregnancy test will be performed on a standard basis. * severe aphasia affecting particularly of receptive nature (NIH Stroke Scale, NIHSS Language subsection ≥2) affecting the ability to understand the purpose of the study and give informed consent * pregnancy
Contact & Investigator
Kirstin-Friederike Heise, Ph.D.
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT07249801 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Visuomotor Skills. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07249801 currently recruiting?
Yes, NCT07249801 is actively recruiting participants. Contact the research team at heisek@musc.edu for enrollment information.
Where is the NCT07249801 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT07249801 clinical trial?
NCT07249801 is sponsored by Medical University of South Carolina. The principal investigator is Kirstin-Friederike Heise, Ph.D. at Medical University of South Carolina. The trial plans to enroll 20 participants.